CY1119008T1 - Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα - Google Patents

Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα

Info

Publication number
CY1119008T1
CY1119008T1 CY20171100498T CY171100498T CY1119008T1 CY 1119008 T1 CY1119008 T1 CY 1119008T1 CY 20171100498 T CY20171100498 T CY 20171100498T CY 171100498 T CY171100498 T CY 171100498T CY 1119008 T1 CY1119008 T1 CY 1119008T1
Authority
CY
Cyprus
Prior art keywords
atranger
muscaric
competitor
beta
battery
Prior art date
Application number
CY20171100498T
Other languages
English (en)
Inventor
Adam Hughes
Daniel Byun
Yan Chen
Melissa Fleury
John Jacobsen
Eric Strangeland
Richard Wilson
Rose Yen
Original Assignee
Theravance Respiratory Company, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119008(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Respiratory Company, Llc filed Critical Theravance Respiratory Company, Llc
Publication of CY1119008T1 publication Critical patent/CY1119008T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Η εφεύρεση αυτή αφορά σε μία ένωση του τύπου Ι• ή φαρμακευτικώς αποδεκτό άλας αυτής. Τέτοιες ενώσεις έχουν αμφότερες τις δραστικότητες ανταγωνιστή μουσκαρινικού υποδοχέα όσο και αγωνιστή β2 αδρενεργικού υποδοχέα. Η εφεύρεση επίσης αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις, μεθόδους και ενδιάμεσα για παρασκευή τέτοιων ενώσεων και μεθόδους χρήσης τέτοιων ενώσεων ως βρογχοδιασταλτικοί παράγοντες για να θεραπεύονται πνευμονικές διαταραχές.
CY20171100498T 2009-04-23 2017-05-09 Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα CY1119008T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17203909P 2009-04-23 2009-04-23
EP10715058A EP2421849B1 (en) 2009-04-23 2010-04-16 Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number Publication Date
CY1119008T1 true CY1119008T1 (el) 2018-01-10

Family

ID=42272140

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100498T CY1119008T1 (el) 2009-04-23 2017-05-09 Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα
CY20191100250T CY1121601T1 (el) 2009-04-23 2019-02-28 Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100250T CY1121601T1 (el) 2009-04-23 2019-02-28 Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα

Country Status (32)

Country Link
US (14) US8138345B2 (el)
EP (3) EP3210981B1 (el)
JP (3) JP5671006B2 (el)
KR (1) KR101769061B1 (el)
CN (2) CN103936716B (el)
AR (1) AR076412A1 (el)
AU (1) AU2010239522B2 (el)
BR (1) BRPI1014877B8 (el)
CA (1) CA2758505C (el)
CL (1) CL2011002637A1 (el)
CO (1) CO6440584A2 (el)
CY (2) CY1119008T1 (el)
DK (3) DK3210981T3 (el)
ES (3) ES2635358T3 (el)
HK (1) HK1165799A1 (el)
HR (3) HRP20130468T1 (el)
HU (2) HUE042975T2 (el)
IL (1) IL215554A (el)
LT (2) LT2599778T (el)
MX (1) MX2011011156A (el)
MY (1) MY158339A (el)
NZ (1) NZ595850A (el)
PL (3) PL2421849T3 (el)
PT (3) PT3210981T (el)
RU (2) RU2676686C2 (el)
SG (1) SG175330A1 (el)
SI (3) SI2599778T1 (el)
SM (1) SMT201300060B (el)
TR (1) TR201903556T4 (el)
TW (2) TWI570115B (el)
WO (1) WO2010123766A1 (el)
ZA (1) ZA201107743B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2599778T (lt) 2009-04-23 2017-08-25 Theravance Respiratory Company, Llc Diamido junginiai, pasižymintys muskarininiam receptoriui antagonistiniu ir beta 2 adrenerginiam receptoriui agonistiniu aktyvumu
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
KR101944564B1 (ko) 2011-06-10 2019-01-31 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
KR20180085068A (ko) 2011-06-10 2018-07-25 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
PL2928890T3 (pl) 2012-12-06 2018-07-31 Chiesi Farmaceutici S.P.A. Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
DK3345904T3 (da) 2012-12-06 2020-08-31 Chiesi Farm Spa Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
WO2016155573A1 (zh) * 2015-03-27 2016-10-06 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
TW201704211A (zh) * 2015-05-14 2017-02-01 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的聯苯衍生物及其在醫藥上的用途
CN107108562B (zh) * 2015-05-14 2020-07-10 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
BR112018015018A2 (pt) * 2016-01-22 2018-12-18 Sichuan Haisco Pharmaceutical Co Ltd derivado de amido azaciclo, método de preparação deste, e aplicação farmacêutica
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
RU2722720C1 (ru) 2016-12-14 2020-06-03 Бейджинг Шоубай Фармасьютикэл Ко., Лтд. Класс бифункциональных соединений со структурой соли четвертичного аммония
EP3625232B1 (en) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
AU783095B2 (en) 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
PT2348032E (pt) 2000-08-05 2015-10-14 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-'(2-furanilcarboxil)oxi]-11.beta.-hidroxi-16.alfa.- metil-3-oxo-androsta-1,4-dieno-17-carbotióico como um agente anti-inflamatório
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
KR20040069319A (ko) * 2001-12-04 2004-08-05 가부시키 가이샤 도쿄 알 앤드 디 급전장치
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239969B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
CA2553293C (en) 2004-01-22 2010-12-14 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2007090477A1 (en) 2006-02-08 2007-08-16 Fuji Oil Europe Edible products with low content of saturated and trans unsaturated fats
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
LT2599778T (lt) 2009-04-23 2017-08-25 Theravance Respiratory Company, Llc Diamido junginiai, pasižymintys muskarininiam receptoriui antagonistiniu ir beta 2 adrenerginiam receptoriui agonistiniu aktyvumu

Also Published As

Publication number Publication date
US20190300504A1 (en) 2019-10-03
US20130137665A1 (en) 2013-05-30
PT2421849E (pt) 2013-05-27
US20160361304A1 (en) 2016-12-15
US20140323733A1 (en) 2014-10-30
US8551978B2 (en) 2013-10-08
EP3210981A1 (en) 2017-08-30
BRPI1014877A2 (pt) 2016-04-12
US9394275B2 (en) 2016-07-19
PT3210981T (pt) 2019-04-01
TR201903556T4 (tr) 2019-04-22
EP2421849B1 (en) 2013-04-03
ZA201107743B (en) 2012-06-27
US20150274697A1 (en) 2015-10-01
RU2015101032A3 (el) 2018-07-30
ES2417339T3 (es) 2013-08-07
SG175330A1 (en) 2011-11-28
CO6440584A2 (es) 2012-05-15
TWI513693B (zh) 2015-12-21
HRP20170960T1 (hr) 2017-09-22
EP2421849A1 (en) 2012-02-29
RU2676686C2 (ru) 2019-01-10
RU2011147374A (ru) 2013-05-27
US9771350B2 (en) 2017-09-26
MY158339A (en) 2016-09-30
US10836744B2 (en) 2020-11-17
PL2421849T3 (pl) 2013-08-30
US10138220B1 (en) 2018-11-27
SI2421849T1 (sl) 2013-07-31
TW201546057A (zh) 2015-12-16
US20170362200A1 (en) 2017-12-21
ES2635358T3 (es) 2017-10-03
LT3210981T (lt) 2019-04-10
US20200165223A1 (en) 2020-05-28
SMT201300060B (it) 2013-07-09
US8816088B2 (en) 2014-08-26
US9572802B2 (en) 2017-02-21
EP2599778A1 (en) 2013-06-05
PL3210981T3 (pl) 2019-06-28
US20170226082A1 (en) 2017-08-10
HRP20190417T1 (hr) 2019-04-19
CA2758505C (en) 2017-03-07
JP5965440B2 (ja) 2016-08-03
IL215554A0 (en) 2011-12-29
EP3210981B1 (en) 2019-01-02
US9975875B2 (en) 2018-05-22
NZ595850A (en) 2013-05-31
US20190047984A1 (en) 2019-02-14
RU2015101032A (ru) 2015-06-27
CN102405218A (zh) 2012-04-04
PL2599778T3 (pl) 2018-01-31
JP2014210816A (ja) 2014-11-13
HK1165799A1 (en) 2012-10-12
BRPI1014877A8 (pt) 2018-03-13
SI3210981T1 (sl) 2019-05-31
TWI570115B (zh) 2017-02-11
AU2010239522B2 (en) 2015-07-02
AR076412A1 (es) 2011-06-08
RU2543716C2 (ru) 2015-03-10
WO2010123766A1 (en) 2010-10-28
JP2015147807A (ja) 2015-08-20
JP2012524783A (ja) 2012-10-18
US10358433B2 (en) 2019-07-23
CN103936716A (zh) 2014-07-23
HUE042975T2 (hu) 2019-07-29
CY1121601T1 (el) 2020-05-29
US20210024493A1 (en) 2021-01-28
US20170096412A1 (en) 2017-04-06
TW201041866A (en) 2010-12-01
DK2421849T3 (da) 2013-07-01
US8138345B2 (en) 2012-03-20
US9682957B2 (en) 2017-06-20
MX2011011156A (es) 2011-11-04
CN103936716B (zh) 2016-09-07
CL2011002637A1 (es) 2012-04-27
US10590107B2 (en) 2020-03-17
HUE035049T2 (en) 2018-05-02
CN102405218B (zh) 2014-06-04
PT2599778T (pt) 2017-06-06
AU2010239522A1 (en) 2011-11-10
ES2715965T3 (es) 2019-06-07
US20130331364A1 (en) 2013-12-12
KR20110138292A (ko) 2011-12-26
DK3210981T3 (en) 2019-04-01
IL215554A (en) 2014-08-31
BRPI1014877B1 (pt) 2020-11-10
US9000173B2 (en) 2015-04-07
JP5671006B2 (ja) 2015-02-18
SI2599778T1 (sl) 2017-08-31
HRP20130468T1 (en) 2013-06-30
LT2599778T (lt) 2017-08-25
DK2599778T3 (en) 2017-06-26
KR101769061B1 (ko) 2017-08-17
US20100273755A1 (en) 2010-10-28
CA2758505A1 (en) 2010-10-28
EP2599778B1 (en) 2017-04-12
BRPI1014877B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1119008T1 (el) Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
EA201690033A3 (ru) Морфинановые соединения
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
CL2007003826A1 (es) Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.
EA201170676A1 (ru) Агонисты рецептора меланокортина
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
EA201001842A1 (ru) Новые соединения, обладающие активностью антагонистов мускариновых рецепторов
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
CY1114205T1 (el) ΕΝΩΣΕΙΣ ΔΙΑΜΙΔΙΩΝ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΥΠΟΔΟΧΕΑ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΥΠΟΔΟΧΕΑ
BRPI0907495A2 (pt) sulfonamidas de imidazolinilmetil arila
TH134761B (th) สารประกอบไดเอไมด์ที่มีแอนทาโกนิสท์แอคทิวิตีต่อหน่วยรับมัสคารินิคและ อโกนิสท์แอคทิวิตีต่อหน่วยรับ b2 อะดรีเนอจิค
TH137278B (th) อนุพันธ์ 2,3-ไดไฮโดร-1h-อินเดน-1-อิล-2,7-ไดแอซาสไพ[3.5]โนเนน